Dr. Brendon Hanson is a Biochemist by training and completed his PhD at La Trobe University in 1998 under the supervision of Prof Nick Hoogenraad studying the mechanism of protein trafficking into mitochondria. Dr. Hanson then came to Singapore with the plan to do a 3 year postdoc at IMCB and spent the next 6 years in the laboratory of Prof Hong Wanjin, once again studying trafficking but this time focusing on the endosome and the role sorting nexins play in this process. Having used antibodies as tools for his research from the beginning, it was only a short leap to make antibodies his main focus and in 2004, Dr. Hanson joined DSO National Laboratories to look at using recombinant antibody technologies to develop detection reagents. Shortly afterward, his focus shifted to therapeutic antibodies, and the selection of antibodies which could be used to treat pandemic influenza. In 2009, the Bio-Defence Therapeutics Lab was established where the focus is to develop technologies to allow rapid antibody development against emerging infectious diseases.